Neurocrine Biosciences, Inc.

Neurocrine Biosciences Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments for neurological and endocrine-related disorders. The primary function of Neurocrine is to address unmet medical needs within these specialized fields through its research and development efforts. The company is well-known for its product Ingrezza, a treatment for tardive dyskinesia, a movement disorder, as well as Orilissa for endometriosis pain, developed in partnership with AbbVie. Neurocrine Biosciences significantly impacts the healthcare and pharmaceutical industries by advancing therapies for complex conditions that lack effective treatments. The company maintains a strong presence in the market through its robust pipeline of potential therapies, targeting diseases like Parkinson’s and congenital adrenal hyperplasia. Founded in 1992 and headquartered in San Diego, California, Neurocrine continues to leverage cutting-edge science to improve patient outcomes, underlining its role as a leader in the biopharmaceutical sector dedicated to neurological and endocrine health.